Literature DB >> 3428667

Pathogenesis of the impaired gall bladder contraction of coeliac disease.

A M Brown1, M J Bradshaw, R Richardson, J G Wheeler, R F Harvey.   

Abstract

We have investigated the possibility that the abnormally decreased gall bladder contraction after meals in patients with coeliac disease might result in part from an abnormality in the gall bladder response to endogenous cholecystokinetic hormones--for example, cholecystokinin and motilin--rather than solely from decreased secretion of such hormones. Eight patients with untreated coeliac disease and nine controls received intravenous infusions of the pure synthetic cholecystokinin analogue caerulein, 2-16 ng/kg/hour. Gall bladder emptying was measured on a minute-by-minute basis using 99mTc-HIDA scans. In the patients with coeliac disease, gall bladder emptying was greatly decreased (34.6 +/- 9.9 v 61.5 +/- 7.5% at 60 minutes, p less than 0.02), and a much greater dose of caerulein was needed to initiate gall bladder contraction (3.80 +/- 1.08 v 1.49 +/- 0.56 ng/kg, p less than 0.02). These results suggest that the abnormal gall bladder contraction in coeliac disease is not simply because of impaired release of cholecystokinin. Although mechanical factors secondary to the increased gall bladder size in patients with coeliac disease might to some extent account for the findings, the alternative explanation is that the gall bladder muscle is for some reason resistant to the action of cholecystokinetic agents. A similar phenomenon affecting the pancreas might contribute to the abnormally decreased pancreatic secretion found in coeliac disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3428667      PMCID: PMC1433691          DOI: 10.1136/gut.28.11.1426

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

1.  Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe.

Authors:  L P Wennogle; D J Steel; B Petrack
Journal:  Life Sci       Date:  1985-04-15       Impact factor: 5.037

2.  Effects of caerulein-related peptides on cholecystokinin receptor bindings in brain and pancreas.

Authors:  M Fujimoto; K Igano; K Watanabe; I Irie; K Inouye; T Okabayashi
Journal:  Biochem Pharmacol       Date:  1985-04-01       Impact factor: 5.858

3.  Rapid evaluation of creatinine clearance.

Authors:  J Braganza; H T Howat
Journal:  Lancet       Date:  1971-05-29       Impact factor: 79.321

4.  Gallbladder inertia and sluggish enterohepatic circulation of bile-salts in coeliac disease.

Authors:  T S Low-Beer; K W Heaton; S T Heaton; A E Read
Journal:  Lancet       Date:  1971-05-15       Impact factor: 79.321

5.  Impaired cholecystokinin-pancreozymin secretion, intraluminal dilution, and maldigestion of fat in sprue.

Authors:  E P DiMagno; W L Go; W H Summerskill
Journal:  Gastroenterology       Date:  1972-07       Impact factor: 22.682

6.  Exocrine pancreatic function in intestinal malabsorption and small bowel disease.

Authors:  B H Novis; S Bank; I N Marks
Journal:  Am J Dig Dis       Date:  1972-06

7.  The exocrine pancreas in intestinal malabsorption syndromes.

Authors:  T Herskovic
Journal:  Am J Clin Nutr       Date:  1968-05       Impact factor: 7.045

8.  Secretion of pancreatic enzymes. I. Response to secretin and pancreozymin.

Authors:  L Zieve; S E Silvis; B Mulford; W D Blackwood
Journal:  Am J Dig Dis       Date:  1966-09

9.  Isolation and structure of caerulein, an active decapeptide from the skin of Hyla caerulea.

Authors:  A Anastasi; V Erspamer; R Endean
Journal:  Experientia       Date:  1967-09-15

10.  The actions of caerulein on the smooth muscle of the gastrointestinal tract and the gall bladder.

Authors:  G Bertaccini; G De Caro; R Endean; V Erspamer; M Impicciatore
Journal:  Br J Pharmacol       Date:  1968-10       Impact factor: 8.739

View more
  9 in total

Review 1.  Impaired intestinal cholecystokinin secretion, a fascinating but overlooked link between coeliac disease and cholesterol gallstone disease.

Authors:  Helen H Wang; Min Liu; Xiaodan Li; Piero Portincasa; David Q-H Wang
Journal:  Eur J Clin Invest       Date:  2017-03-08       Impact factor: 4.686

Review 2.  Cholecystectomy for biliary dyskinesia: how did we get there?

Authors:  Klaus Bielefeldt; Shreyas Saligram; Susan L Zickmund; Anwar Dudekula; Mojtaba Olyaee; Dhiraj Yadav
Journal:  Dig Dis Sci       Date:  2014-09-06       Impact factor: 3.199

Review 3.  Update on the Molecular Mechanisms Underlying the Effect of Cholecystokinin and Cholecystokinin-1 Receptor on the Formation of Cholesterol Gallstones.

Authors:  Helen H Wang; Piero Portincasa; David Q-H Wang
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

4.  Gallbladder and pancreatic dysfunction in celiac disease.

Authors:  N S Mann
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

5.  Plasma cholecystokinin and gallbladder responses to increasing doses of bombesin in celiac disease.

Authors:  P W Thimister; W P Hopman; G Rosenbusch; J B Jansen
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

6.  Lack of endogenous cholecystokinin promotes cholelithogenesis in mice.

Authors:  H H Wang; M Liu; P Portincasa; P Tso; D Q-H Wang
Journal:  Neurogastroenterol Motil       Date:  2015-11-25       Impact factor: 3.598

Review 7.  Glyphosate, pathways to modern diseases II: Celiac sprue and gluten intolerance.

Authors:  Anthony Samsel; Stephanie Seneff
Journal:  Interdiscip Toxicol       Date:  2013-12

Review 8.  An Update on the Lithogenic Mechanisms of Cholecystokinin a Receptor (CCKAR), an Important Gallstone Gene for Lith13.

Authors:  Helen H Wang; Piero Portincasa; Min Liu; Patrick Tso; David Q-H Wang
Journal:  Genes (Basel)       Date:  2020-11-29       Impact factor: 4.096

9.  Gallbladder motility in children with celiac disease before and after gluten-free diet.

Authors:  Subhamoy Das; Sadhna B Lal; Vybhav Venkatesh; Anish Bhattacharya; Akshay Saxena; B R Thapa; Satya Vati Rana
Journal:  Ann Gastroenterol       Date:  2021-02-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.